General Information of Drug (ID: DMNRLA7)

Drug Name
DMP-695/696 Drug Info
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Investigative [1]
Cross-matching ID
PubChem CID
56603766
TTD Drug ID
DMNRLA7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Telavancin DM58VQX Staphylococcus infection 1B5Y Approved [1]
Pexacerfont DMBJ15R Anxiety disorder 6B00-6B0Z Phase 2/3 [2]
SSR125543 DMGJEB8 Anxiety disorder 6B00-6B0Z Phase 2 [3]
ONO-2333Ms DMOT0WR Anxiety disorder 6B00-6B0Z Phase 2 [4]
GSK561679 DMEVARK Alcohol dependence 6C40.2 Phase 2 [5]
Tildacerfont DMAB8LH Congenital adrenal hyperplasia 5A71.01 Phase 2 [6]
GSK586529 DM5E9LX Anxiety disorder 6B00-6B0Z Phase 1 [5]
GW876008 DMAXRBI Irritable bowel syndrome DD91.0 Discontinued in Phase 2 [2]
CP-316,311 DMZ76EM Major depressive disorder 6A70.3 Discontinued in Phase 2 [2]
CRA1000 DMWMBIV Anxiety disorder 6B00-6B0Z Preclinical [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Corticotropin-releasing factor receptor 1 (CRHR1) TT7EFHR CRFR1_HUMAN Antagonist [1]

References

1 A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
2 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
3 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
4 Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6 Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Nov 30;186(1):R1-R14.